How much profit has Diaceutics made this year?
Diaceutics has made -1.89 M GBP this year.
Diaceutics Net Income 2024
Diaceutics Net Income
-1.89 M GBP
Ticker
DXRX.L
ISIN
GB00BJQTGV64
WKN
A2PF80
In 2024, Diaceutics's profit amounted to -1.89 M GBP, a 8.31% increase from the -1.75 M GBP profit recorded in the previous year.
The Diaceutics Net Income history
| YEAR | NET INCOME (undefined GBP) |
|---|---|
| 2029e | - |
| 2028e | - |
| 2027e | 8.32 |
| 2026e | 5.28 |
| 2025e | 1.72 |
| 2024e | -1.89 |
| 2023 | -1.75 |
| 2022 | 0.72 |
| 2021 | 0.56 |
| 2020 | 0.26 |
| 2019 | 0.4 |
| 2018 | 0.63 |
| 2017 | 0.66 |
| 2016 | 0.75 |
Diaceutics Revenue, EBIT, Net Income GB00BJQTGV64 · A2PF80
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Diaceutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Diaceutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Diaceutics’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Diaceutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Diaceutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Diaceutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Diaceutics’s growth potential.
Diaceutics Revenue, EBIT and net profit per share
| Date | Diaceutics Revenue | Diaceutics EBIT | Diaceutics Net Income |
|---|---|---|---|
| 2029e | 67.12 M GBP | 0 GBP | 0 GBP |
| 2028e | 59.93 M GBP | 0 GBP | 0 GBP |
| 2027e | 56.75 M GBP | 11.12 M GBP | 8.32 M GBP |
| 2026e | 47.99 M GBP | 5.82 M GBP | 5.28 M GBP |
| 2025e | 38.23 M GBP | 902,182.5 GBP | 1.72 M GBP |
| 2024e | 30.14 M GBP | -2.53 M GBP | -1.89 M GBP |
| 2023 | 23.7 M GBP | -3.02 M GBP | -1.75 M GBP |
| 2022 | 19.5 M GBP | 575,000 GBP | 724,000 GBP |
| 2021 | 13.94 M GBP | 550,000 GBP | 561,000 GBP |
| 2020 | 12.7 M GBP | -270,000 GBP | 263,000 GBP |
| 2019 | 13.44 M GBP | 2.09 M GBP | 397,880 GBP |
| 2018 | 10.37 M GBP | 1.41 M GBP | 632,310 GBP |
| 2017 | 7.37 M GBP | 901,250 GBP | 663,190 GBP |
| 2016 | 4.59 M GBP | 882,290 GBP | 747,140 GBP |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2016 | 4.59 M GBP | 882,290 GBP | 747,140 GBP |
| 2017 | 7.37 M GBP | 901,250 GBP | 663,190 GBP |
| 2018 | 10.37 M GBP | 1.41 M GBP | 632,310 GBP |
| 2019 | 13.44 M GBP | 2.09 M GBP | 397,880 GBP |
| 2020 | 12.7 M GBP | -270,000 GBP | 263,000 GBP |
| 2021 | 13.94 M GBP | 550,000 GBP | 561,000 GBP |
| 2022 | 19.5 M GBP | 575,000 GBP | 724,000 GBP |
| 2023 | 23.7 M GBP | -3.02 M GBP | -1.75 M GBP |
| 2024e | 30.14 M GBP | -2.53 M GBP | -1.89 M GBP |
| 2025e | 38.23 M GBP | 902,182.5 GBP | 1.72 M GBP |
| 2026e | 47.99 M GBP | 5.82 M GBP | 5.28 M GBP |
| 2027e | 56.75 M GBP | 11.12 M GBP | 8.32 M GBP |
| 2028e | 59.93 M GBP | 0 GBP | 0 GBP |
| 2029e | 67.12 M GBP | 0 GBP | 0 GBP |
Diaceutics stock margins GB00BJQTGV64 · A2PF80
The Diaceutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Diaceutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Diaceutics.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Diaceutics's sales revenue. A higher gross margin percentage indicates that the Diaceutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Diaceutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Diaceutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Diaceutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Diaceutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Diaceutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Diaceutics Margin History
| Diaceutics Gross margin | Diaceutics Profit margin | Diaceutics EBIT margin | Diaceutics Profit margin |
|---|---|---|---|
| 2029e | 83.15 % | 0 % | 0 % |
| 2028e | 83.15 % | 0 % | 0 % |
| 2027e | 83.15 % | 19.59 % | 14.66 % |
| 2026e | 83.15 % | 12.13 % | 11.01 % |
| 2025e | 83.15 % | 2.36 % | 4.5 % |
| 2024e | 83.15 % | -8.38 % | -6.28 % |
| 2023 | 83.15 % | -12.73 % | -7.37 % |
| 2022 | 85.83 % | 2.95 % | 3.71 % |
| 2021 | 87.73 % | 3.94 % | 4.02 % |
| 2020 | 74.54 % | -2.13 % | 2.07 % |
| 2019 | 76.7 % | 15.53 % | 2.96 % |
| 2018 | 65.57 % | 13.55 % | 6.1 % |
| 2017 | 66.31 % | 12.23 % | 9 % |
| 2016 | 57.86 % | 19.23 % | 16.28 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2016 | 57.86 % | 19.23 % | 16.28 % |
| 2017 | 66.31 % | 12.23 % | 9 % |
| 2018 | 65.57 % | 13.55 % | 6.1 % |
| 2019 | 76.7 % | 15.53 % | 2.96 % |
| 2020 | 74.54 % | -2.13 % | 2.07 % |
| 2021 | 87.73 % | 3.94 % | 4.02 % |
| 2022 | 85.83 % | 2.95 % | 3.71 % |
| 2023 | 83.15 % | -12.73 % | -7.37 % |
| 2024e | 83.15 % | -8.38 % | -6.28 % |
| 2025e | 83.15 % | 2.36 % | 4.5 % |
| 2026e | 83.15 % | 12.13 % | 11.01 % |
| 2027e | 83.15 % | 19.59 % | 14.66 % |
| 2028e | 83.15 % | 0 % | 0 % |
| 2029e | 83.15 % | 0 % | 0 % |
Diaceutics Aktienanalyse
What does Diaceutics do?
Diaceutics PLC is a consulting company specializing in optimizing diagnostic and treatment solutions for patients with serious and complex diseases. It was founded in 2005 by Peter Keeling in Belfast, Northern Ireland, and is now headquartered in London, UK. The company is listed on the London Stock Exchange and has offices in Europe, Asia, North America, and Australia. The business model of Diaceutics is based on the increasing number of personalized medicines on the market, targeting specific genetic markers to enable more accurate diagnosis and treatment. The company specializes in analyzing laboratory data to help doctors and pharmaceutical companies identify the specific tests needed for treating individual patients. It also offers a variety of services to optimize the use of tests in patient care. Diaceutics operates in three divisions: Diagnostic Services, Data and Analytics Services, and Strategy and Implementation Services. Diagnostic Services include optimizing diagnostic tests and identifying patient populations that would benefit from a particular treatment. Data and Analytics Services involve setting up data and analytics platforms to gain insights into the use of diagnostic tests in clinical practice. Strategy and Implementation Services support pharmaceutical companies in conducting campaigns to promote the use of diagnostic tests and increase the availability of personalized medicines. Diaceutics' products and services also include Diagnostic Insights products, providing insights into the use of diagnostic tests in various therapy areas. These insights help pharmaceutical companies optimize their personalization strategies and enhance the effectiveness of their medicines. The company also offers diagnostic programs aimed at promoting the use of diagnostic tests in clinical practice and eliminating barriers to the use of personalized medicines. Diaceutics has established partnerships with many of the world's leading diagnostic and pharmaceutical companies and also provides consulting services to support them in developing personalization strategies. Its clients include both pharmaceutical and diagnostic companies. Overall, Diaceutics has become a leading provider of personalized healthcare solutions. It occupies a unique position in the market by focusing on the intersection of diagnostics and therapy and being able to offer a wide range of products and services. Given the rapid progress in personalized medicine, Diaceutics will continue to play a significant role in optimizing diagnosis and treatment strategies and providing better care for patients. Diaceutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Diaceutics's Profit Margins
The profit margins of Diaceutics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Diaceutics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Diaceutics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Diaceutics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Diaceutics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Diaceutics stock
How has the profit developed compared to last year?
The profit has increased by 8.31% compared to last year increased
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Diaceutics publish its earnings?
Diaceutics publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Diaceutics?
The profits of Diaceutics are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Diaceutics?
You can learn more about the earnings of Diaceutics by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Diaceutics pay?
Over the past 12 months, Diaceutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Diaceutics is expected to pay a dividend of 0 GBP.
What is the dividend yield of Diaceutics?
The current dividend yield of Diaceutics is .
When does Diaceutics pay dividends?
Diaceutics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Diaceutics?
Diaceutics paid dividends every year for the past 0 years.
What is the dividend of Diaceutics?
For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.
In which sector is Diaceutics located?
Diaceutics is assigned to the 'Health' sector.
Wann musste ich die Aktien von Diaceutics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Diaceutics from 10/8/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 10/8/2024.
When did Diaceutics pay the last dividend?
The last dividend was paid out on 10/8/2024.
What was the dividend of Diaceutics in the year 2023?
In the year 2023, Diaceutics distributed 0 GBP as dividends.
In which currency does Diaceutics pay out the dividend?
The dividends of Diaceutics are distributed in GBP.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Diaceutics
Our stock analysis for Diaceutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Diaceutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
